![\"\"](\"https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/08\/20260801_Heidelberg_University_Hospital_Technology_and_Modalities-768x432.png\")
<\/p>\n<\/p>\n
Company<\/strong><\/p>\n Heidelberg University Hospital<\/p>\n Event Type<\/strong><\/p>\n Published Research (Peer-Reviewed, Phase I\/II Translational Biomarker Study)<\/p>\n Modality<\/strong><\/p>\n Autologous anti-CD19 CAR-T cell therapy (CD28 and 4-1BB costimulatory domains)<\/p>\n Asset<\/strong><\/p>\n CD27-negative\/CD39-negative functional effector-cell biomarker (research-stage, not a commercial product)<\/p>\n Target<\/strong><\/p>\n CD19; biomarker profiling of CD27\/CD39 T-cell differentiation and dysfunction states<\/p>\n Disease Area<\/strong><\/p>\n Relapsed or refractory CD19-positive lymphoid malignancies (diffuse large B-cell, follicular, and mantle-cell lymphoma)<\/p>\n Investigators deeply profiled anti-CD19 CAR-T products and leukapheresis starting material from the phase I\/II HD-CAR-1 dose-escalation study. Among 28 treated patients, six achieved responses despite receiving low doses. These low-dose responders were enriched for non-exhausted effector and effector-memory-like CAR-T cells, and the absolute number of CD27-negative\/CD39-negative cells discriminated responders better than relative cell-state frequencies.<\/p>\n The result supports a potentially practical product-quality biomarker for under-dosed or out-of-specification CAR-T products. It does not establish that lower total doses are equivalent to standard doses, that the biomarker is prospectively validated for product release, or that manufacturing specifications should change. The clinical cohort was small and non-randomized, and commercial-product validation used early post-infusion blood cells as a proxy because the investigators could not directly test commercial infusion material.<\/p>\n HD-CAR-1 is an open-label, single-center phase I\/II trial of a third-generation CD19 CAR containing CD28 and 4-1BB costimulatory domains in relapsed or refractory CD19-positive lymphoid malignancies. Patients received 1 million to 200 million CAR-T cells per square meter. The analysis grouped eight high-dose responders, twelve low-dose non-responders, and six low-dose responders. Forty percent of lymphoma patients had long-term responses. Reported toxicity was limited to grade 1 or 2 cytokine-release syndrome, with no immune-effector-cell-associated neurotoxicity, other neurological toxicity, or dose-limiting toxicity in the reported cohort.<\/p>\n The investigators identified CD27-negative\/CD39-negative CD4 and CD8 CAR-T cells as a simple marker of a functional effector-like state. In vitro, these cells showed strong immediate cytotoxicity but limited proliferative plasticity. T-cell-rich and pro-inflammatory, antigen-presenting myeloid states in the leukapheresis material were associated with functional products, whereas regulatory myeloid programs and sustained IL-4, IL-10, IL-13, or TGF-beta exposure promoted CD39-positive dysfunctional states.<\/p>\n The study does not argue that total CAR-T dose is unimportant: across the cohort, dose correlated with in-vivo expansion and progression-free survival, and low-dose patients were less likely to respond. The more precise finding is that some low-dose products contained enough immediately cytotoxic effector cells to cross a functional threshold. This helps explain exceptional responses after manufacturing yield falls below target but cannot define a universally safe minimum dose.<\/p>\n Absolute cell counts are biologically appropriate when comparing products with very different total doses; percentages can make a small product appear compositionally favorable even when it contains too few active cells. The CD27-negative\/CD39-negative phenotype is attractive because it is compatible with flow-cytometric release testing. Yet it is response-associated, not proven causal or exclusive. The authors explicitly note that more plastic CD27-positive\/CD39-positive cells can proliferate and generate effector progeny, so a single marker pair cannot capture the full balance between immediate killing, expansion, and persistence.<\/p>\n The association between starting-material myeloid state and final-product function suggests that product failure can reflect a reversible manufacturing environment rather than an immutable patient defect. If validated, depletion of suppressive myeloid cells, cytokine washout, or altered culture conditions could improve low-yield products. However, the experiments do not establish which intervention is clinically optimal, and manipulating culture toward terminal effectors could improve early killing while reducing long-term persistence.<\/p>\n One interpretation is that absolute CD27-negative\/CD39-negative counts could rescue selected out-of-specification products that would otherwise be discarded, expanding access and reducing manufacturing waste, supported by consistent discrimination across dose levels, functional killing assays, and an independent cross-disease validation cohort that included commercial CD19- and BCMA-directed products. A second interpretation is that the marker mainly captures favorable patient and manufacturing context and may not generalize into a product-release rule, given the non-randomized design, heterogeneous lymphoma indications, multiple dose levels, and potential confounding by disease burden or cell fitness.<\/p>\n This is a positive\/uncertain technology signal. It changes the framing of low-dose CAR-T from a simple quantity problem to a quantity-plus-quality problem and provides a tractable candidate biomarker. The data are not sufficient to relax release specifications or claim that under-dosed products are generally effective. Insilens treats the study as a strong biomarker hypothesis with manufacturing relevance, pending prospective validation against actual infusion products and durable outcomes.<\/p>\n Autologous CAR-T therapy requires leukapheresis, genetic engineering, cell expansion, release testing, lymphodepletion, and reinfusion. Manufacturing can fail to reach a target cell number, producing an out-of-specification product that may be unavailable, reimbursed differently, or used only under exceptional pathways. A biomarker that identifies functional low-yield products could reduce waste, but an unreliable threshold could expose patients to ineffective therapy when disease progression leaves little time for remanufacture.<\/p>\n HD-CAR-1 is sponsored by Heidelberg University Hospital and studies a third-generation CD19 CAR with CD28 and 4-1BB signaling domains after fludarabine and cyclophosphamide lymphodepletion. The reported lymphoma cohorts included diffuse large B-cell, follicular, and mantle-cell lymphoma. CD27 is associated with T-cell differentiation and costimulation; CD39 marks adenosine-generating, chronically stimulated or dysfunctional states in several settings.<\/p>\n Signal Importance is rated 4\/5 with a Positive\/uncertain direction. Confidence in the underlying facts is High, supported by peer review, mechanistic assays, and an independent validation cohort; confidence in the interpretation is Medium-High, limited by sample size, non-randomized design, cohort heterogeneity, and the lack of prospective release-testing validation.<\/p>\n","protected":false},"excerpt":{"rendered":" Investigators deeply profiled anti-CD19 CAR-T products and leukapheresis starting material from the phase I\/II HD-CAR-1 dose-escalation study. Among 28 treated patients, six achieved responses despite receiving low doses. These low-dose responders were enriched for…<\/p>\n","protected":false},"author":1,"featured_media":2364,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1,4],"tags":[182,55,247,248],"class_list":["post-2362","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-all-categories","category-technology-modalities","tag-diffuse-large-b-cell-lymphoma","tag-follicular-lymphoma","tag-heidelberg-university-hospital","tag-mantle-cell-lymphoma"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2362","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=2362"}],"version-history":[{"count":2,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2362\/revisions"}],"predecessor-version":[{"id":2365,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2362\/revisions\/2365"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/2364"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=2362"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=2362"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=2362"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}Summary<\/h4>\n
Clinical interpretation<\/h4>\n
Biomarker interpretation<\/h4>\n
Manufacturing interpretation<\/h4>\n
Alternative interpretations and validation gate<\/h4>\n
Signal Extraction<\/h4>\n
\n
InSilens Take<\/h4>\n
Company and Product Background<\/h4>\n
Signal Assessment<\/h4>\n